PD. I doubt Germany ( and probably also France ) will cover Vazkepa at a price acceptable to AMRN without independent confirmation of at least the R-IT PCI risk reduction numbers .... How AMRN generates that independent confirmation ...MITGATE or RWE ( real world evidence ) remains to be seen . Meanwhile we have HEART UK starting July 5th with AMRN running a symposia on Icosapent-ethyly ( Vazkepa ) So we should see in the 3 months following that ...how effective AMRN has been in generating sales in the UK . Thx to Capt for tracking that data . Re Denner vs KM . KM is a salesman and would have milked AMRN for as long as he could. Denner is motivated to at least get his money back and will try and maneuver the Co into a position where he can sell it. JMO Kiwi